NCT05874479 Reducing AIR Pollution Exposure to Lower Blood PRESSURE Among New York City Public Housing Residents
| NCT ID | NCT05874479 |
| Status | Recruiting |
| Phase | — |
| Sponsor | NYU Langone Health |
| Condition | Blood Pressure |
| Study Type | INTERVENTIONAL |
| Enrollment | 440 participants |
| Start Date | 2023-12-20 |
| Primary Completion | 2027-09 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 440 participants in total. It began in 2023-12-20 with a primary completion date of 2027-09.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Fine particulate matter \<2.5 µm (PM2.5) air pollution is the fifth leading risk factor for global mortality, with the largest portion of deaths due to cardiovascular disease (CVD). While several mechanisms are responsible, PM2.5-induced elevations in blood pressure (BP) may be relevant. Indoor portable air cleaners (PACs) are a novel approach to reduce exposure to PM2.5 and potentially lower blood pressure. The current study is being conducted to provide evidence that PACs reduce PM2.5 exposure and lower systolic blood pressure (SBP) in key patient populations.
Eligibility Criteria
Inclusion Criteria: * self-reported nonsmokers living in a nonsmoking household. * adults living with hypertension (HTN) from NYC public housing. Exclusion Criteria: * History of major known arrhythmias (e.g. atrial flutter or fibrillation, ventricular tachycardia). * Screening systolic BP ≥160 mm Hg or diastolic BP ≥100 mm Hg (i.e. severe hypertension by the 2017 ACC/AHA BP guideline). * A change in drug regimen in the prior 2 weeks or a planned change in drug regimen during the first 30 days for those taking antihypertensive medication. * Current smoking or living with an active smoker who smokes indoors * Planned travel out of NYC for ≥2 weeks in next 6 months * Incarcerated * Pregnant * Unable/unwilling to consent * Established cardiovascular disease * End-stage renal disease (chronic kidney disease stage IV or on dialysis) * Barrier to technology use (e.g., visual or hearing impairment) * Lung disease requiring oxygen * Cancer receiving treatment
Contact & Investigator
Jonathan Newman
PRINCIPAL INVESTIGATOR
NYU Langone Health
Frequently Asked Questions
Who can join the NCT05874479 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 100 Years, studying Blood Pressure. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05874479 currently recruiting?
Yes, NCT05874479 is actively recruiting participants. Contact the research team at AirPressureNYC@nyulangone.org for enrollment information.
Where is the NCT05874479 trial being conducted?
This trial is being conducted at New York, United States.
Who is sponsoring the NCT05874479 clinical trial?
NCT05874479 is sponsored by NYU Langone Health. The principal investigator is Jonathan Newman at NYU Langone Health. The trial plans to enroll 440 participants.